Kaplan-Meier curves of (A) progression-free survival and (B) overall survival.

Kaplan-Meier curves of (A) progression-free survival and (B) overall survival.

Kaplan-Meier curves of (A) progression-free survival and (B) overall survival. NE, not estimated; HR, hazard ratio; CI, confidence interval.

Enregistré dans:

Détails bibliographiques
Auteur principal:	Lu Xie (20428615) (author)
Publié:	2025
Sujets:	Diseases Apatinib Mesylate Osteosarcoma Background Osteosarcoma Ifosfamide/etoposide
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Supplementary Figure S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
par: Yan Zhou (15053225)
Publié: (2025)

Supplementary Table 1 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
par: Dhruv Chachad (14954640)
Publié: (2025)

Supplementary Table 2 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
par: Dhruv Chachad (14954640)
Publié: (2025)

Supplementary Table 3 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
par: Dhruv Chachad (14954640)
Publié: (2025)

Supplementary Table 4 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
par: Dhruv Chachad (14954640)
Publié: (2025)

Supplementary Table 5 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
par: Dhruv Chachad (14954640)
Publié: (2025)

Kaplan Meier survival curves for new DENV seropositivity during the 2-year study period from Dec 2019 – Feb 2022..
par: Bethel Alebel Bayrau (22676588)
Publié: (2025)

Kaplan Meier survival curves for new CHIKV seropositivity during the 2- year study period from Dec 2019 – Feb 2022.
par: Bethel Alebel Bayrau (22676588)
Publié: (2025)

Kaplan–Meier curve showing 24-month cumulative primary patency stratified by venographic and procedural factors.
par: Chang Hoon Oh (16786347)
Publié: (2025)

The MBM-Index as an independent predictor of overall survival (OS) in melanoma.
par: Jingxin Zeng (18773484)
Publié: (2025)

Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan
par: Kazuhito Suzuki (22688384)
Publié: (2025)

Supplementary Table S10 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
par: Anfal Alsadhan (15907475)
Publié: (2025)

Supplementary Table S4 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
par: Anfal Alsadhan (15907475)
Publié: (2025)

Supplementary Table S5 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
par: Anfal Alsadhan (15907475)
Publié: (2025)

Supplementary Table S6 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
par: Anfal Alsadhan (15907475)
Publié: (2025)

Supplementary Table S7 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
par: Anfal Alsadhan (15907475)
Publié: (2025)

Supplementary Table S8 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
par: Anfal Alsadhan (15907475)
Publié: (2025)

Supplementary Table S9 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
par: Anfal Alsadhan (15907475)
Publié: (2025)

The data for the standard curves.
par: Fei Chen (13690)
Publié: (2025)

Prediction of early graft loss at the individual level and identification of crucial factors: (A) Survival curves for all patients who experienced graft loss are plotted.
par: Raiki Yoshimura (22676573)
Publié: (2025)

Supplemental Materials
par: Jinyu Zhang (22288396)
Publié: (2025)

Reducing Anxiety and Improving Adherence in Kidney Transplant Recipients: A Cognitive Behavioral Intervention -Based Approach
par: Chao Zhong (22679885)
Publié: (2025)

<b>Intensive care decision-making, survival and dying well:</b><b>How do the experiences of intensive care patients and their end-of-life wishes affect their willingness to accept intensive care treatment at different chances of survival?</b>
par: Thomas Donaldson (22653461)
Publié: (2025)

Overall acceptability of the MNH-EPI-COS.
par: Karen Klein (6650600)
Publié: (2025)

The standard curves by the methods of SDM (<i>P </i> = 0.0036) and SSDM (<i>P</i> < 0.001).
par: Fei Chen (13690)
Publié: (2025)

Protocell Survival Networks in Spatially Modulated Chemical Gradients
par: Shuqi Wu (582226)
Publié: (2025)

Protocell Survival Networks in Spatially Modulated Chemical Gradients
par: Shuqi Wu (582226)
Publié: (2025)

Protocell Survival Networks in Spatially Modulated Chemical Gradients
par: Shuqi Wu (582226)
Publié: (2025)

Protocell Survival Networks in Spatially Modulated Chemical Gradients
par: Shuqi Wu (582226)
Publié: (2025)

Protocell Survival Networks in Spatially Modulated Chemical Gradients
par: Shuqi Wu (582226)
Publié: (2025)

Protocell Survival Networks in Spatially Modulated Chemical Gradients
par: Shuqi Wu (582226)
Publié: (2025)

Protocell Survival Networks in Spatially Modulated Chemical Gradients
par: Shuqi Wu (582226)
Publié: (2025)

Protocell Survival Networks in Spatially Modulated Chemical Gradients
par: Shuqi Wu (582226)
Publié: (2025)

Protocell Survival Networks in Spatially Modulated Chemical Gradients
par: Shuqi Wu (582226)
Publié: (2025)

Participant characteristics in the overall cohort and in groups classified by dysmenorrhea score.
par: Maika Nariai (22676447)
Publié: (2025)

Painting background
par: Son Nguyen (22474540)
Publié: (2025)

Painting background
par: Son Nguyen (22474540)
Publié: (2025)

Painting background
par: Son Nguyen (22474540)
Publié: (2025)

Painting background
par: Son Nguyen (22474540)
Publié: (2025)

Airborne Spread of SARS-CoV-2 Between Rooms in a Sealed, Mechanically Ventilated Ward: Evidence from a Hospital Outbreak Investigation
par: Yo Ishigaki (11052900)
Publié: (2025)

Cannot write session to /tmp/vufind_sessions/sess_m5s2jfo1ha1f345fku3l2gmonv